The Joint Action on Personalised Cancer Medicine (JA PCM) is inviting patients, citizens and public stakeholders to two online consultations on 26 and 27 October 2026. The discussions will contribute to the development of a possible public-private partnership (PPP) for personalised cancer medicine that could continue beyond the Joint Action.
JA PCM has already held exchanges with private sector actors. The two new sessions will bring in perspectives from patients and citizens and from public organisations. Participants will be invited to share what they expect from a future partnership, how it should be designed and what it should achieve for patients, society and European health systems.
Patients’ and Citizens’ Perspective
Towards a Public-Private-Partnership in Personalised Cancer Medicine: Patients’ and Citizens’ Perspective
- Date: Monday, 26 October 2026
- Time: 16:30-17:30 Central European Time (CET)
- Format: Online via Webex
This session welcomes patients, survivors, carers, patient advocates, representatives of patient and citizen organisations and anyone interested in improving cancer care and research across Europe. No scientific or technical background is required. Participants’ experiences and views will inform the next steps in JA PCM’s dialogue on a possible partnership.
Public Stakeholders’ Perspective
Towards a Public-Private-Partnership in Personalised Cancer Medicine: Public Stakeholders’ Perspective
- Date: Tuesday, 27 October 2026
- Time: 16:30-17:30 Central European Time (CET)
- Format: Online via Webex
The second session is aimed at representatives of national and European public initiatives in cancer, personalised medicine, health data and health systems. This includes ministries, funding agencies, public health institutes, research infrastructures, regulatory bodies, Health Technology Assessment bodies and EU-level projects, networks and policy teams.
Towards a Structured Dialogue
JA PCM brings together 29 European countries and 151 partner organisations to advance personalised cancer care. The four-year project, which runs from 2025 to 2029, is working towards a sustainable cross-border network for personalised cancer medicine. Its current public-private dialogue is intended to help define a collaborative framework that can support its pilot activities and develop beyond the lifetime of the project.